The Quantellect read.As of Nov 19, 2026, 3 active firms cover Rigel Pharmaceuticals Inc: 2 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $49.00 to $85.00, a moderate spread. The average target of $71.67 sits 69% above the current $42.51. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.52 next quarter toward $4.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy267%
Neutral133%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$71.67
+68.6% upside
Average target across 3 active firms as of Nov 19, 2026 vs $42.51 current
Highest Target$85.00
Average Target$71.67
Lowest Target$49.00
Detailed analyst forecasts for RIGL
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 2 of 3 active firms rate RIGL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RIGL EPS & revenue forecast
EPS · NEXT QUARTER
$0.52
Range $0.52 – $0.52 · 1 analysts · +18% YoY
Next period, 1 analysts expect Rigel Pharmaceuticals Inc to earn $0.52 a share (range $0.52 – $0.52), versus $0.44 a year earlier. Full-year consensus is $3.34, growing to $4.78 the year after.
REVENUE · NEXT QUARTER
$77.8M
Range $70.0M – $85.6M · 1 analysts · +32% YoY
Revenue is expected to reach $77.8M (range $70.0M – $85.6M), +32.3% year-over-year. Full-year consensus is $306.3M, rising to $374.4M next year.
Top analysts covering Rigel Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RIGL.
#1
Kristen Kluska
Cantor Fitzgerald · Rank #232
Neutral
$43.00+1.2% to target
Overall win rate
38%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$85.00+100.0% to target
Overall win rate
34%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$83.00+95.2% to target
Overall win rate
38%
+ Follow
#4
Allison Bratzel
Piper Sandler
Neutral
$49.00+15.3% to target
Coverage
—
+ Follow
#5
FH
Farzin Haque
Jefferies
Buy
$42.00-1.2% to target
Coverage
—
+ Follow
RIGL stock forecast FAQ
What is RIGL's average 12-month price target?+
The 3 active firms with a live target average $71.67 for Rigel Pharmaceuticals Inc over the next 12 months, ranging from a $85.00 high to a $49.00 low, as of Nov 19, 2026.
Is RIGL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RIGL?+
The Street-high target is $85.00 (HC Wainwright & Co.), and the Street-low is $49.00 (Piper Sandler). The average of all 3 active-firm targets is $71.67.
How many active Wall Street firms cover RIGL?+
3 active firms have a recognized rating on Rigel Pharmaceuticals Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RIGL?+
Among analysts who currently cover RIGL, Kristen Kluska of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #232). Their current call is Neutral with a $43.00 target.
What is Rigel Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.52 per share (range $0.52 – $0.52) across 1 analysts. Full-year EPS is projected at $3.34, rising to $4.78 the following year.
How much revenue is Rigel Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $77.8M (range $70.0M – $85.6M). Full-year revenue is projected at $306.3M, growing to $374.4M next year.
Have analysts been upgrading or downgrading RIGL lately?+
As of Nov 19, 2026, 2 of 3 active firms rate RIGL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RIGL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.